Only about 2.6 million Americans had received a COVID-19 vaccine going into the last day of December, putting the United States far short of the government's target to vaccinate 20 million people this month.
Seattle public health officials have so little COVID-19 funding on hand they worry they will have to shut down some virus testing sites as they mount a campaign to dose their 2.3 million residents with Pfizer Inc's and Moderna Inc's vaccines.
JERUSALEM (Reuters) -Israel is carefully husbanding supplies as it races to vaccinate all vulnerable citizens by late January and push for an early exit from the COVID-19 pandemic, officials said on Thursday.
The world risks a "moral catastrophe" if COVID-19 vaccinations are delayed in Africa while wealthier regions inoculate their entire populations, the head of the continent's disease control body said on Thursday.
Singapore reported five locally transmitted COVID-19 cases on Thursday, its highest number in nearly three months, and was seeking to verify two others suspected of being infected by a highly contagious variant first discovered in Britain.
Dozens of elderly South Korean coronavirus patients were transferred from nursing homes to hospitals this week after criticism that government policy had led to a spike in deaths among the vulnerable residents.
China was ahead in the global race to develop coronavirus vaccines with the most candidates in late stage of trials earlier in the year and its first approval of a homemade shot for the general public came on Thursday, yet with no detailed efficacy data.
South Africa will have a firm date on when it will get COVID-19 vaccine in the first few days of January, a senior health ministry official told a television news channel on Thursday.
Israel expects to begin receiving Moderna Inc.'s coronavirus vaccines by March "at the latest", Health Minister Yuli Edelstein told Ynet TV on Thursday.
Turkey's trials of COVID-19 vaccines from China's Sinovac will reach interim results in mid-January with at least 40 infected cases, a key threshold for approvals, the coordinator of the trials study told Reuters on Thursday.
No comments:
Post a Comment